Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
MediWound Community
NasdaqGM:MDWD Community
1
Narratives
written by author
0
Comments
on narratives written by author
3
Fair Values set
on narratives written by author
Create a narrative
MediWound
Latest
Undervalued
Overvalued
Community Investing Ideas
MediWound
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
FDA Approval And Phase III Trial Will Expand Wound Care
Key Takeaways Strong EscharEx results and strategic partnerships boost potential sales growth, leveraging Medicare policies and Phase III trials for greater revenue prospects. NexoBrid's FDA approval and geographic expansion increase market opportunities, while new manufacturing capabilities aim to meet demand, supporting long-term revenue growth.
View narrative
US$31.00
FV
37.3% undervalued
intrinsic discount
25.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
MDWD
MDWD
MediWound
Your Fair Value
US$
Current Price
US$19.43
134.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-24m
84m
2015
2018
2021
2024
2025
2027
2030
Revenue US$84.0m
Earnings US$12.1m
Advanced
Set Fair Value